Deal-Making

AGC builds on Provention partnership with diabetes mAb production

AGC Biologics’ Bothwell, Washington site is commercially manufacturing Provention Bio’s type 1 diabetes (T1D) monoclonal antibody Tzield (teplizumab). Provention Bio said it selected AGC Bio to produce Tzield – the first authorized drug that can delay onset T1D –  after the contract development manufacturing organization (CDMO) supported the drug ahead of its approval by the US Food and Drug Administration (FDA) in November 2022. Tepilzumab is manufactured in two main stages: the upstream process followed by the downstream process,” Kevin…

Normax and MTIF take mRNA tech to UK Uni

Normax Biomed has partnered with Medical Technologies Innovation Facility (MTIF) at Nottingham Trent University (NTU) to provide access to Telesis Bio’s BioXP system. The agreement, of which financial details have not been divulged, will see NTU develop and discover gene therapies and messenger RNA (mRNA) vaccines using the BioXP system. Irish mRNA-based company Normax claims the BioXP platform, created by Californian firm Telesis Bio, is the world’s first commercially available end-to-end fully automated bench top synthetic biology system . The…

Pfizer to acquire Abzena’s NC manufacturing plant

Pfizer is set to acquire a drug substance facility in Sanford, North Carolina from Abzena to expand capacity and support its CentreOne clients. British contract development manufacturing organization (CDMO) Abzena announced the addition of a sixth global site in the US in January 2021. Three months later, the firm revealed it had selected Sanford, North Carolina as the site of a biologics manufacturing facility, which would cost the firm over $200 million and be equipped with 12x 2,000 L bioreactors.…

Catalent and Avantor ink multi-year supply and services deal

Avantor will supply Catalent with clinical and production materials, services, and laboratory supplies. Avantor, a company that provides products and services to clients in the life sciences space, has entered into a multi-year supply and services agreement with contract development manufacturing organization (CDMO) Catalent. No financial details of the deal are being disclosed but the partnership will see Catalent work with Avantor across more than 50 facilities situated across the globe. “Avantor is an existing supplier to Catalent,” a spokesperson…

Hospira experience will aid Abzena success, says new CEO

The experience of leading the operational turnaround at Hospira provides a robust framework for advancing Abzena’s success, says newly appointed CEO Matthew Stober. Contract development manufacturing organization (CDMO) Abzena, which focuses on antibody drug conjugates (ADCs) and biologic molecules, announced this month that Stober would replace Jonathon Goldman as CEO. Most recently, Stober held position of CEO at CastleVax and Istari Oncology. However, while all of his past job roles are undoubtedly influential, his experience of leading the turnaround of…

Vector Bio and iBET team to scale-up gene delivery processes

The project aims to develop Vector BioPharma’s gene delivery platform using iBET’s bioprocess and analytical methods.   The partnership between the two parties is in support of Vector Bio’s CMC (chemistry, manufacturing, and controls) development and the announcement follows the Swiss firm’s $30 million Series A fundraising in August 2022. To begin with, the multiphase partnership aims to advance an analytical method suitable for full-to-empty capsid ratio quantification from in-process as well as final purified samples. “Vector’s proprietary technology uses a…

Valo selects Exothera to develop oncolytic adenovirus

Valo Therapeutics Oy (ValoTx) has selected CDMO Exothera to develop a large-scale production process for clinical development of its oncolytic adenovirus, VALO-D102. ValoTx’s VALO-D102 is an oncolytic adenovirus, which the firm says is an essential component of its immuno-oncology platform PeptiCRAd (Peptide-coated Conditionally Replicating Adenovirus). “We take an oncolytic adenovirus (VALO-D102) and add immunogenic positively charged tumor peptides, which are adsorbed onto the negatively charged viral capsid to create PeptiCRAd,” a spokesperson for ValoTx told us. The platform works by…

Astrea adds chromatography offering through Delta buy

Astrea Bioseparations has acquired Delta Precision, a manufacturer of chromatography columns for the biopharma space. The deal, of which financial details remain undisclosed, sees Astrea Bioseparations acquire Delta Precision. The firm says the acquisition will enable its product offering to include an entire range of chromatography columns for biomanufacturing. Astrea claims Delta’s products are recognized in the field for their wide range of applications, protein purification, vaccine production, drug development, and ease of use. A spokesperson for Astrea told BioProcess…

CytomX and Moderna partner to develop mRNA-based therapeutics

CytomX Therapeutics will combine its Probody platform with Moderna’s mRNA technology to create and advance therapeutics for oncology and non-oncology conditions. The partnership and licensing agreement, which aims to generate investigational messenger RNA (mRNA) based conditionally activated therapies, will use Moderna’s mRNA technologies alongside CytomX’s Probody therapeutic platform. According to CytomX, its platform enables proteins to activate in diseased tissue while remaining masked in systemic circulation, expanding the availability of new targets for the potential treatment of a large range…

MaxCyte signs electroporation deal with Catamaran

Catamaran Bio will have non-exclusive clinical and commercial rights to use MaxCyte’s Flow Electroporation technology and ExPERT platform. MaxCyte has signed a strategic platform licence (SPL) with Catamaran, a company focused on developing off-the-shelf chimeric antigen receptor natural killer (CAR-NK) cell therapies used to treat a wide range of cancers, particularly solid tumors. While financial details of this deal remain undisclosed, MaxCyte has confirmed it will receive platform licensing fees and program-related revenue under the terms of the agreement. “The…